FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896717142> ?p ?o ?g. }

• W2896717142 endingPage "1356" @default.
• W2896717142 startingPage "1350" @default.
• W2896717142 abstract "BACKGROUND: The risk of anal carcinoma after previous diagnosis of anal intraepithelial neoplasia III is unclear. OBJECTIVE: The purpose of this study was to estimate the risk of anal carcinoma in patients with anal intraepithelial neoplasia III and to identify predictors for subsequent malignancy. DESIGN: This was a retrospective review using the Surveillance, Epidemiology, and End Results registry (1973–2014). SETTING: The study was composed of population-based cancer registries from the United States. PATIENTS: Patients who were diagnosed with anal intraepithelial neoplasia III were included. MAIN OUTCOME MEASURES: The primary outcome was rate of subsequent anal squamous cell carcinoma. Predictors for anal cancer were identified using logistic regression and Cox proportional hazard models. RESULTS: A total of 2074 patients with anal intraepithelial neoplasia III were identified and followed for a median time of 4.0 years (interquartile range, 1.8–6.7 y). Of the cohort, 171 patients (8.2%) subsequently developed anal cancer. Median time from anal intraepithelial neoplasia III diagnosis to anal cancer diagnosis was 2.7 years (interquartile range, 1.1–4.5 y). Fifty-two patients (30.4%) who developed anal carcinoma were staged T2 or higher. Ablative therapies for initial anal intraepithelial neoplasia III were associated with a reduction in the risk of anal cancer (OR = 0.3 (95% CI, 0.1–0.7); p = 0.004). Time-to-event analysis revealed that the 5-year incidence of anal carcinoma after anal intraepithelial neoplasia III was 9.5% or ≈1.9% per year. LIMITATIONS: The registry did not record HIV status, surveillance schedule, use of high-resolution anoscopy, or provider specialty. CONCLUSIONS: In the largest published cohort of patients with anal intraepithelial neoplasia III, ≈10% of patients were projected to develop anal cancer within 5 years. Nearly one third of anal cancers were diagnosed at stage T2 or higher despite a previous diagnosis of anal intraepithelial neoplasia III. Ablative procedures were associated with a decreased risk of cancer. This study highlights the considerable rate of malignancy in patients with anal intraepithelial neoplasia III and the need for effective therapies and surveillance. See Video Abstract at http://links.lww.com/DCR/A764." @default.
• W2896717142 created "2018-10-26" @default.
• W2896717142 creator A5009890711 @default.
• W2896717142 creator A5023457344 @default.
• W2896717142 creator A5036297830 @default.
• W2896717142 creator A5045768064 @default.
• W2896717142 creator A5050959903 @default.
• W2896717142 creator A5077530610 @default.
• W2896717142 creator A5084109798 @default.
• W2896717142 creator A5086586295 @default.
• W2896717142 date "2018-12-01" @default.
• W2896717142 modified "2023-10-17" @default.
• W2896717142 title "What Is the Risk of Anal Carcinoma in Patients With Anal Intraepithelial Neoplasia III?" @default.
• W2896717142 cites W1530811954 @default.
• W2896717142 cites W1982019844 @default.
• W2896717142 cites W1993165426 @default.
• W2896717142 cites W2013606441 @default.
• W2896717142 cites W2013874226 @default.
• W2896717142 cites W2021716350 @default.
• W2896717142 cites W2051129590 @default.
• W2896717142 cites W2051692103 @default.
• W2896717142 cites W2055556351 @default.
• W2896717142 cites W2067818215 @default.
• W2896717142 cites W2071377262 @default.
• W2896717142 cites W2086069847 @default.
• W2896717142 cites W2088785857 @default.
• W2896717142 cites W2091964860 @default.
• W2896717142 cites W2317573925 @default.
• W2896717142 cites W2325176861 @default.
• W2896717142 cites W2332799841 @default.
• W2896717142 cites W2413104908 @default.
• W2896717142 cites W2509208600 @default.
• W2896717142 cites W2509801830 @default.
• W2896717142 cites W2751960360 @default.
• W2896717142 cites W2752306638 @default.
• W2896717142 cites W4211141601 @default.
• W2896717142 cites W4255255845 @default.
• W2896717142 doi "https://doi.org/10.1097/dcr.0000000000001219" @default.
• W2896717142 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6219933" @default.
• W2896717142 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30303884" @default.
• W2896717142 hasPublicationYear "2018" @default.
• W2896717142 type Work @default.
• W2896717142 sameAs 2896717142 @default.
• W2896717142 citedByCount "43" @default.
• W2896717142 countsByYear W28967171422018 @default.
• W2896717142 countsByYear W28967171422019 @default.
• W2896717142 countsByYear W28967171422020 @default.
• W2896717142 countsByYear W28967171422021 @default.
• W2896717142 countsByYear W28967171422022 @default.
• W2896717142 countsByYear W28967171422023 @default.
• W2896717142 crossrefType "journal-article" @default.
• W2896717142 hasAuthorship W2896717142A5009890711 @default.
• W2896717142 hasAuthorship W2896717142A5023457344 @default.
• W2896717142 hasAuthorship W2896717142A5036297830 @default.
• W2896717142 hasAuthorship W2896717142A5045768064 @default.
• W2896717142 hasAuthorship W2896717142A5050959903 @default.
• W2896717142 hasAuthorship W2896717142A5077530610 @default.
• W2896717142 hasAuthorship W2896717142A5084109798 @default.
• W2896717142 hasAuthorship W2896717142A5086586295 @default.
• W2896717142 hasBestOaLocation W28967171422 @default.
• W2896717142 hasConcept C119060515 @default.
• W2896717142 hasConcept C121608353 @default.
• W2896717142 hasConcept C126322002 @default.
• W2896717142 hasConcept C207103383 @default.
• W2896717142 hasConcept C2776235491 @default.
• W2896717142 hasConcept C2777546739 @default.
• W2896717142 hasConcept C2777661416 @default.
• W2896717142 hasConcept C2778527826 @default.
• W2896717142 hasConcept C2779399171 @default.
• W2896717142 hasConcept C2779534503 @default.
• W2896717142 hasConcept C2779840525 @default.
• W2896717142 hasConcept C2910643260 @default.
• W2896717142 hasConcept C29456083 @default.
• W2896717142 hasConcept C44249647 @default.
• W2896717142 hasConcept C71924100 @default.
• W2896717142 hasConcept C90924648 @default.
• W2896717142 hasConceptScore W2896717142C119060515 @default.
• W2896717142 hasConceptScore W2896717142C121608353 @default.
• W2896717142 hasConceptScore W2896717142C126322002 @default.
• W2896717142 hasConceptScore W2896717142C207103383 @default.
• W2896717142 hasConceptScore W2896717142C2776235491 @default.
• W2896717142 hasConceptScore W2896717142C2777546739 @default.
• W2896717142 hasConceptScore W2896717142C2777661416 @default.
• W2896717142 hasConceptScore W2896717142C2778527826 @default.
• W2896717142 hasConceptScore W2896717142C2779399171 @default.
• W2896717142 hasConceptScore W2896717142C2779534503 @default.
• W2896717142 hasConceptScore W2896717142C2779840525 @default.
• W2896717142 hasConceptScore W2896717142C2910643260 @default.
• W2896717142 hasConceptScore W2896717142C29456083 @default.
• W2896717142 hasConceptScore W2896717142C44249647 @default.
• W2896717142 hasConceptScore W2896717142C71924100 @default.
• W2896717142 hasConceptScore W2896717142C90924648 @default.
• W2896717142 hasIssue "12" @default.
• W2896717142 hasLocation W28967171421 @default.
• W2896717142 hasLocation W28967171422 @default.
• W2896717142 hasLocation W28967171423 @default.
• W2896717142 hasLocation W28967171424 @default.
• W2896717142 hasOpenAccess W2896717142 @default.

• next